thalidomide inhalation (VP02) / Vicore Pharma - LARVOL DELTA

Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates (Vicore Pharma Press Release) - "Vicore Pharma Holding AB...announced pipeline updates as the company continues to focus on development of C21 for idiopathic pulmonary fibrosis (IPF). The updates announced today include confirmation that development of the lead program, C21 for IPF is on track, with final Phase 2a AIR data in the first half of next year. In addition, start-up activities for the global, double-blind, placebo-controlled, 52-week, Phase 2b ASPIRE study of C21 for IPF are progressing with initiation expected in the first half of 2024. Development of the Almee digital therapy advances as well, with topline results of the COMPANION pivotal study for anxiety associated with pulmonary fibrosis expected to be reported in January 2024....Vicore will discontinue development of the preclinical IMiD program, inhaled thalidomide for IPF cough."

Clinical data • Discontinued • New P2b trial • P2a data • Idiopathic Pulmonary Fibrosis • Immunology

Interim report July - September 2021 (PRNewswire) - "The first patients have completed treatment in the ongoing multinational, open-label phase 2 clinical trial with C21, the AIR study....The company expects to start a GLP toxicology study with VP02, the inhaled thalidomide product for IPF and IPF cough, by the end of 2021."

Preclinical • Trial status • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Interim report April - June 2021 (PRNewswire) - "In May, in a collaborative program with Alex Therapeutics, we launched the development of VP04, a proprietary prescription digital therapeutic for patients with idiopathic pulmonary fibrosis (IPF)....Results from the phase 2 AIR study of C21 in IPF are expected at the end of 2022 at current recruiting plan and outlook as patient recruitment continues in India, Ukraine, the United Kingdom and Russia. The VP02 program is ready to initiate GLP toxicity studies during the fall of 2021 followed by a phase 1 study in 2022."

New molecule • New P1 trial • P2 data • Preclinical • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Vicore Pharma intends to carry out a directed share issue (PRNewswire) - “Vicore Pharma Holding AB…today announces its intention to carry out a directed share issue corresponding to approximately SEK 300 million to institutional investors through an accelerated bookbuilding procedure (the 'Directed New Share Issue')….Vicore Pharma intends to use the potential issue proceeds to finance…strengthening the Company's IPF franchise…”

Financing • Idiopathic Pulmonary Fibrosis • Respiratory Diseases